Abstract: The present invention relates to methods and composition for use in the treatment of retinal degeneration, in particular retinal degeneration due to retinal pigment epithelium dysfunction.

Abstract: The present invention relates to a device (2) for providing a liquid medium with a controlled flow rate and with a controlled concentration of a dissolved gas, the device (2) comprising: —a liquid reservoir (4) provided with: —at least one gas inlet (7); —at least one gas outlet (8); and—at least one liquid outlet (9); —an admission line (5) configured to provide a gaseous medium into the liquid reservoir (4), the admission line (5) being connected to the at least one gas inlet (7) and comprising at least one control valve (12); and an emission line (6) configured to withdraw the gaseous medium from the liquid reservoir (4), the emission line (6) being connected to the at least one gas outlet (8) and comprising at least one control valve (15). The present invention further relates to an assembly comprising said device, and to a method for providing a liquid medium with a controlled flow rate and with a controlled concentration in a dissolved gas.

Abstract: The invention relates to a method for characterizing a visual system of a subject using measures of the sensitivity to contrast, the visual system comprising visual signal processing elements each having an impact on the sensitivity to contrast, wherein a visual test where visual patterns having different spatiotemporal frequencies and with varying luminance levels and with varying levels of visual degradation of the visual patterns are shown to a subject to measure the sensitivity to contrast of said subject, is performed, wherein a predetermined response model of a visual system is preestablished on the basis of a determination of the visual signal processing element that predominantly limits the sensitivity to contrast for each value of luminance and spatiotemporal frequency, said predetermined response model relating the visual signal processing elements predominantly limiting the sensitivity to contrast to the luminances and to the spatiotemporal frequencies, wherein at least one of the visual signal pro

Abstract: The present invention relates to a surgical kit for use in a craniectomy procedure, the surgical kit comprising: a medical device to be implanted in a cranial bone of a patient, the medical device (10) including several transducers for emitting ultrasound waves for treatment of brain tissue, a surgical accessory (20) intended to be positioned on the cranial bone of the patient, the surgical accessory (20) including a body whose outer perimeter defines the dimensions of an opening that is to be made in the cranial bone of the patient in order to receive the medical device, characterized in that the surgical accessory (20) comprises a plurality of holes (201) formed in the body, the position of each hole (201) on the body coinciding with the position of the axis of symmetry of a respective transducer, such that the accessory is able to be positioned optimally through the joint use of a neuronavigation system.

Abstract: A method for depositing an object, including: —approaching, in an enclosure, a holder in the direction of a carrier substrate, then—transferring, in the enclosure, the object from the holder to an area for depositing the carrier substrate. The transfer step is preferably carried out when the inside of the enclosure is in a vacuum at a pressure below 10?6 bar.

Abstract: The present invention relates to a compound of the following general formula (I): or a pharmaceutically acceptable salt and/or solvate thereof, for use as drug, particularly intended for inhibiting a programmed cell death route selected from the group consisting of ferroptosis, oxytosis and cellular necroptosis. The present invention also relates to a compound of general formula (I) for use as a drug for neuroprotection as well as for preventing and/or treating disorders associated with cellular necroptosis or ferroptosis. The present invention also relates to a pharmaceutical composition comprising a compound of general formula (I), or a pharmaceutically acceptable salt and/or solvate thereof. The present invention also encompasses the use of a compound of the general formula (I) for organs preservation.

Abstract: A photoconductive switch for generating or detecting terahertz radiation (TR) is provided. The photoconductive switch may comprise at least a first and a second pair of electrodes (EV, EH, EGR) on a surface (SS) of a photoconductive substrate, wherein the electrodes of the first pair are separated by a first gap comprising at least a plurality of first rectilinear sections (GV) extending along a first direction (x) and the electrodes of the second pairs are separated by a second gap comprising at least a plurality of second sections (GH) extending along a second direction (y), different from the first direction. The photoconductive switch may further comprise a patterned opaque layer (PML) selectively masking portions of the gaps between the electrodes. Methods and devices for generating and detecting terahertz radiation comprising such photoconductive switches are also provided.

Abstract: Optical system comprising two optical fibres which are configured to define between them a Fabry-Perot cavity, and a connecting element bonded to each of the two optical fibres, the connecting element defining a through-passage, at least one of the two optical fibres comprising an end portion arranged in the through-passage and bonded to the connecting element, the two optical fibres extending along an axis and being separated from one another by a distance Le parallel to the axis, one of the optical fibres being bonded to the connecting element at a first bonding zone, and the other optical fibre being bonded to the connecting element at a second bonding zone separated from the first bonding zone by distance parallel to the axis.

Abstract: Devices and methods for reversibly stimulating neuronal cells in a subject. The devices include a module for generating ultrasounds at 4 MHz or more to stimulate neuronal cells expressing mechanosensitive channels with the ultrasounds. The methods include expressing mechanosensitive channels into neuronal cells and exposing the cells to ultrasounds at 4 MHz or more. Also, the use of the methods or devices for visual restoration in a subject.

Abstract: An implantable ultrasound generating treating device (12) to induce spinal cord or spinal nerves treatment, suitable for implantation in the spinal canal and comprises an elongate support member (22, 32) and an array of several treatment transducers (20) distributed along the elongate support member. The several treatment transducers (20) comprise radial transducers emitting an ultrasound treatment beam oriented radially, wherein the treatment transducers (20) have a resonant frequency comprised between 0.5 and 4 MHz. The device has articulating portions so that the implantable device can adapt its shape to a curved elongation path. Also disclosed is an apparatus including the implantable ultrasound generating treating device and methods comprising inserting the implantable ultrasound generating treating device (12) inside the spinal canal of the spine of the patient.

Abstract: Disclosed are anti-angiogenic agents that target Pfn1:actin interaction. Also disclosed are compounds for treating ocular diseases or conditions. Further disclosed are compounds for treating cancer.

Abstract: A method for manufacturing a superconducting LC-type resonator of the type including at least one high-resistivity substrate on which are printed an inductive meander, a first so-called lower electrode and a second so-called upper electrode arranged opposite the first so as to form together a capacitor connected in parallel with the inductive meander, as well as inductive coupling means dedicated to the resonator, in which a sacrificial aluminium layer is deposited between the first and second electrodes. Also disclosed is the superconducting LC-type resonator thus obtained and the use of such a resonator for detecting the noise of a millimetre photon.

Abstract: The use of recombinant AAV vectors expressing a molecule of interest in a method for treating diseases or conditions affecting the nervous system in a subject in need thereof, or in a method for increasing or inducing expression of the molecule of interest in the nervous system of a subject.

Abstract: An apparatus having an implantable ultrasound generating treating device to induce brain disorder treatment, suitable for implantation in or under the skull bone of a patient, includes several ultrasound generating transducers, which are connectable by a common electrical connection circuit to a generator, and wherein the ultrasound generating transducers each have one or several operating frequencies. The transducers include the group of transducers having several transducers driven by a same electrical drive signal, and connected to the generator system by a common electrical connection circuit, where the electric drive signal serves both as power signal and as a control signal for operating selectively, within said group, at least one or the other of a first transducer or sub-group of transducers, and of a second transducer or sub-group of transducers. The apparatus is also used to treat brain disorders.

Abstract: Electroacoustic device having a transducer including a piezoelectric substrate, first and second electrodes of inverse polarity having respective first and second tracks provided on said substrate, the first and second tracks spiraling around a same center (C), the transducer being configured for generating a swirling ultrasonic surface wave in the substrate.

Abstract: Several new vector-promoter combinations to overcome the limitations associated with AAV-mediated cone transduction in the fovea are provided. The delivery modality relies on a cone-specific promoter and result in high-level transgene expression compatible with optogenetic vision restoration. Methods of expressing a polynucleotide of interest in the cone photoreceptors of a subject comprising subretinal delivery of a therapeutically effective amount of a recombinant AAV9-derived vector comprising a VP1 capsid protein as set forth in SEQ ID NO: 11 and the polynucleotide of interest under the control of the pR1.7 promoter as set forth in SEQ ID NO: 12 are also provided.

Abstract: An in vitro method of classifying a subject suspected to suffer from an acute event including the steps of: determining neopterin concentration in a biological sample obtained from the subject, comparing the concentration with a predetermined reference neopterin concentration, and assigning the subject to a risk group based on the comparison of the neopterin concentration with the predetermined reference neopterin concentration.

Abstract: Disclosed is a method utilizing (R)-2-(2-aminothiazol-4-yl)-4?-[2-[(2-hydroxy-2-phenylethyl)amino]ethyl]acetic acid anilide or an analogue, pharmaceutically acceptable salt or solvate thereof for the treatment of a retinal disease, more specifically using mirabegron for the treatment of age-related macular degeneration. Also Disclosed is a pharmaceutical composition, a medicament and a kit for the treatment of age-related macular degeneration.

Abstract: The invention is in the field of therapy of antibody deficiencies. Inventors demonstrate for the first time in both controls and IgA-deficient patients, systemic anti-microbiota IgG responses correlate with reduced inflammation suggesting that systemic IgG responses contribute to the gut microbiota confinement. Furthermore, SIgAd-associated inflammation is inversely correlated with systemic anti-commensal IgG responses, which may thus serve as a second line of defense. Altogether, these data suggest that systemic IgG and intestinal IgA cooperate in different body compartments to limit systemic pro-inflammatory pathways. As selective IgA deficient patients harbour elevated seric anti-commensal IgG levels, these findings suggest that in selective IgA deficiency, microbiota confinement is obtained at the price of a strong inflammatory response.

Abstract: A process for pre-concentration and detection of at least one single-stranded nucleic acid target molecule, the process comprising the steps of generating a flow of liquid comprising at least one magnetic nanoparticle in a micro-channel and a plurality of single-stranded nucleic acid probe molecules attached to the nanoparticle, generating an alternating magnetic field in the part of the micro-channel using an electromagnet, the magnetic field having an intensity and frequency that are suitable for causing magnetic hyperthermia of the nanoparticles so as to cause denaturing of the duplex formed by the single-stranded nucleic acid target molecule and the single-stranded nucleic acid probe molecule, and detecting the single-stranded target molecule dispersed in the liquid.